CyprusUpdated 30 July 20266 min read

Psychedelic Therapy in Cyprus: Every Legal Route in 2026

Written by the editorial team · fact-checked against primary sources · clinical review scheduled.

On this page

  1. At a glance
  2. The public system: nothing we could confirm
  3. Private ketamine at the Cyprus rTMS centre
  4. What we don't know yet
  5. Psilocybin and MDMA: research only
  6. What to expect in treatment
  7. Risks and who should not start
  8. Frequently asked questions
  9. Sources

If you are looking into psychedelic-assisted treatment in Cyprus — for yourself or for someone close to you — the honest summary for July 2026 is short: we found no public-system route, and one private route we could verify. A specialised neuromodulation centre in Nicosia offers ketamine treatment for depression alongside rTMS, run by clinicians who publish on their own patient outcomes. Psilocybin and MDMA are research-only. This guide covers what the route involves, how to start, and — unusually much for this series — what we could not confirm; you can begin orienting yourself with our eligibility check.

TL;DR We could not find any GESY decision or listing covering esketamine or ketamine treatment for depression in Cyprus, so treat the public route as unconfirmed. The route that works is private: the Cyprus rTMS centre in Nicosia, directed by psychiatrist Dr George Mikellides, offers intramuscular ketamine for treatment-resistant depression — typically six to eight injections over three to four weeks, each session about 40–45 minutes — and has published peer-reviewed research comparing ketamine with rTMS in its own patients. Prices are not published; contact the clinic for a written quote. Psilocybin and MDMA remain research-only.

At a glance

RouteSubstanceStatus in CyprusWho qualifiesCost
Private ketamineKetamine (IM, off-label)Legal; offered at the Cyprus rTMS centre in NicosiaClinic screening: treatment-resistant depression and related conditionsNot published — ask for a written quote
GESY-covered esketamineEsketamine (Spravato)Not confirmed — no coverage decision found
Psilocybin therapyPsilocybinResearch only
MDMA therapyMDMAResearch only
Clinical trialsPsilocybin, MDMA, ketamineNo Cypriot site in our tracked registry dataStudy-specific criteriaFree

How Cyprus compares across the continent: Europe-wide reimbursement map.

The public system: nothing we could confirm

Cyprus's General Healthcare System (GESY) covers a broad medicines catalogue, but we could not find any published GESY listing, tender or decision covering esketamine (Spravato) or ketamine treatment for depression, nor any state hospital advertising such a service. That is not proof of absence — it is an unverified gap, and we say so plainly. If public coverage matters to your decision, ask a GESY psychiatrist directly whether esketamine can be prescribed and funded in your case, and treat any answer you get as worth documenting. For how esketamine coverage works where it does exist, see our Europe-wide reimbursement map.

Private ketamine at the Cyprus rTMS centre

The one provider we have verified is the Cyprus rTMS centre in Nicosia, a private clinic specialising in treatment-resistant depression, directed by psychiatrist Dr George Mikellides, Clinical Assistant Professor of Psychiatry at the University of Nicosia Medical School. Alongside repetitive transcranial magnetic stimulation, the centre offers ketamine treatment given as intramuscular injections: a full course is typically six to eight injections over three to four weeks, with each treatment session lasting about 40–45 minutes; short-term side effects such as nausea and fatigue usually settle quickly (Famagusta News).

What sets the centre apart in this region is that its clinicians publish: a study of 24 treatment-resistant depression patients treated at the centre, comparing ketamine with rTMS, appeared in Frontiers in Psychiatry and found significant symptom improvement in both groups with no significant difference between them (Mikellides et al., 2021). That is a small retrospective sample, not a verdict on which treatment is better — but it means the clinic's claims can be checked against its own published data, which is rare.

How to start and what it costs. Ketamine here is used off-label, which is legal and standard practice; admission follows the clinic's own psychiatric screening, and you can self-refer by contacting the centre. Prices are not published — ask for a written cost breakdown for the full course, including assessment and follow-up, before starting. To see what is listed for Cyprus, browse providers in Cyprus.

Access pathway for private clinics in Cyprus: self-referral, medical screening, treatment plan and self-pay, follow-up and integration
Access pathway for private clinics in Cyprus: self-referral, medical screening, treatment plan and self-pay, follow-up and integration

What we don't know yet

An honest list of the gaps in our verification, as of 30 July 2026:

  • GESY status. We found no coverage decision for esketamine or ketamine either way — unconfirmed, not confirmed-negative.
  • Whether Spravato is available at all in Cyprus. We could not verify pharmacy distribution of the branded spray or any clinic offering it.
  • Prices. The Cyprus rTMS centre does not publish ketamine pricing; we have no verified figures.
  • Other providers. One verified clinic does not mean only one exists — private psychiatric clinics in Limassol or Larnaca may offer ketamine without publishing it.

Psilocybin and MDMA: research only

Psilocybin and MDMA remain controlled substances in Cyprus with no medical-access route (Psychedelic Alpha tracker), and our tracked registry data shows no Cypriot psychedelic trial site. The realistic option is a trial elsewhere in Europe — our trials guide explains how to search. Anyone offering psilocybin or MDMA therapy commercially in Cyprus today is operating illegally.

What to expect in treatment

Whichever route you take, the shape of care is similar and worth picturing in advance. Treatment begins with a screening appointment: the clinician reviews your psychiatric and medication history, checks your cardiovascular health and current medicines, and confirms the diagnosis before anything is scheduled. This is also where contraindications are caught.

On a Spravato day you self-administer the nasal spray in the practice or clinic under supervision, then stay for an observation period of roughly two hours while staff monitor blood pressure, heart rate and how you feel; dissociation and a temporary rise in blood pressure are expected and settle as the drug clears. You must not drive for the rest of the day, so arrange a ride home. Induction is typically more frequent at first and then tapers based on measured response, always combined with a continuing oral antidepressant.

A ketamine infusion is usually given intravenously over about 40–60 minutes with the same vital-sign monitoring and a recovery period afterwards; KAP programs wrap the dosing in preparation and integration sessions with a therapist. Where a legal psychedelic-therapy route exists (a compassionate-use programme, a regulated PAT programme or a clinical trial — availability differs by country), dosing days are long and closely supervised — two trained professionals including a physician stay with you — and sit inside a broader plan of preparation, general psychiatric care and integration. In every setting the medicine is one part of the plan: screening, monitoring and follow-up are what make it safe, and psychotherapy or integration is what helps the effect last.

Risks and who should not start

These treatments are generally well tolerated under supervision, but they are not for everyone, which is exactly what screening is for. Common, transient effects during or shortly after a session include dissociation (a detached, dreamlike feeling), nausea, mild perceptual changes, and a short-lived rise in blood pressure and heart rate; these resolve as the drug is metabolised. Treatment may be inappropriate, or require particular caution and specialist evaluation, when any of the following apply:

  • Uncontrolled hypertension or significant cardiovascular instability, including a history of aneurysmal vascular disease, because of the temporary rise in blood pressure.
  • A personal or family history of psychosis or bipolar disorder — a particular caution for classic psychedelics such as psilocybin, which legal programmes screen for carefully.
  • Pregnancy or breastfeeding.
  • Substance-use concerns, particularly patterns of compulsive use.

A responsible provider screens for all of these before the first dose. If a clinic is willing to treat you without that assessment, treat it as a warning sign — see our clinic-choice guide. To see who is listed near you, browse providers in Germany.

Frequently asked questions

Does GESY cover ketamine or esketamine treatment?

We could not confirm any coverage. No published GESY listing or decision was found, which leaves the status genuinely unknown — ask a GESY psychiatrist directly, and let us know what you learn.

What does ketamine treatment at the Cyprus rTMS centre involve?

Intramuscular ketamine injections after psychiatric screening: a full course is typically six to eight injections over three to four weeks, each session around 40–45 minutes including observation. The centre combines this with its neuromodulation practice and has published outcome data on its own patients.

How much does it cost?

Prices are not published. Request a written quote for the complete course — screening, injections, monitoring and follow-up — before committing, and compare with figures elsewhere in our cost guide.

Can I get psilocybin or MDMA therapy in Cyprus?

No. Both are research-only, no Cypriot trial is in our tracked data, and no legal clinical route exists. Watch the registries or consider trial sites elsewhere in Europe.

Sources

  1. Cyprus rTMS centre — Nicosia
  2. Cyprus rTMS centre: Ketamine treatment
  3. Famagusta News: Pioneering research on depression in Cyprus — ketamine vs rTMS study details
  4. Mikellides et al., Frontiers in Psychiatry (2021): Comparison of ketamine and rTMS in treatment-resistant depression
  5. GESY — General Healthcare System of Cyprus
  6. EMA: Spravato (esketamine) EPAR
  7. Psychedelic Alpha: Worldwide psychedelic laws tracker
  8. ClinicalTrials.gov

This guide is for general information only and is not medical advice, a diagnosis, or a recommendation of any treatment. Regulations, prices and coverage rules can change; always verify current requirements with the Health Insurance Organisation (GESY), the clinic, or a licensed clinician who knows your history. If you are in crisis, contact your local emergency number or a crisis line immediately.

This guide awaits review by a licensed medical professional.

Continue reading

Looking for a provider? Browse the directory by country or read how listings are verified.